Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis.
Semaglutide ranked first in reducing cardiovascular mortality among antidiabetic drugs for patients with type 2 diabetes and chronic kidney disease, but further studies are needed to confirm these findings.
Where it sits
this study against the rest of the semaglutide corpusSummary and findings
This network meta-analysis evaluated the efficacy and safety of various antidiabetic drugs in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). A total of 39,844 participants were included, with outcomes assessed through surface under the cumulative ranking curve (SUCRA) values. Semaglutide was noted to rank first in reducing cardiovascular mortality.
Abstract
Background A number of novel antidiabetic drugs have been developed. These drugs include sodium-glucose cotransporter 2 inhibitors (SGLT-2is), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase-4 inhibitors (DPP-4is). However, the optimal medication for individuals with type 2 diabetes mellitus (T2DM) and comorbid chronic kidney disease (CKD) has not been established. To this end, this study was conducted to compare specific novel antidiabetic drugs regarding efficacy and safety. Methods PubMed, Embase, Cochrane Library, and Web of Science databases were searched for publications dated as of July 9, 2025. Cochrane risk of bias tool version 2.0 (RoB 2.0) was applied to measure the quality of the publications, and R 4.2.2 and Stata 15.1 were used to execute a Bayesian network meta-analysis (NMA). Primary outcomes encompassed major adverse cardiovascular events (MACEs), composite renal outcomes, and all-cause mortality (ACM). Secondary outcomes comprised adverse events (AEs), hypoglycemia, and cardiovascular death. Results This NMA incorporated 30 studies, involving 39,844 participants with T2DM and comorbid CKD. The interventions were ranked by performance in various outcomes using the surface under the cumulative ranking curve (SUCRA) values. Sotagliflozin ranked first in reducing MACEs (SUCRA: 90.57%). Empagliflozin ranked first in improving composite renal outcomes (SUCRA: 89.76%) and reducing ACM (SUCRA: 72.38%). Canagliflozin ranked first in reducing AEs (SUCRA: 83.37%). Dapagliflozin + exenatide ranked first in reducing hypoglycemic events (SUCRA: 77.74%). Semaglutide ranked first in reducing cardiovascular mortality (SUCRA: 89.46%). Conclusion Novel antidiabetic drugs offer benefits for patients with T2DM and comorbid CKD. However, the optimal intervention varies for different outcomes. Further clinical studies are anticipated to validate these findings. Systematic review registration https://www.crd.york.ac.uk/prospero/, identifier CRD420251146144.
Background
The paper addresses the clinical question of how novel antidiabetic drugs perform in patients with type 2 diabetes who also have chronic kidney disease. Previous studies have indicated that managing diabetes in this population is complex due to the interplay between glycemic control and kidney function. This study is significant as it aims to synthesize existing evidence to inform treatment decisions.
Methods
This research is a network meta-analysis, which typically aggregates data from multiple studies to compare the efficacy and safety of various interventions. The specific population characteristics, sample size, dose, and duration of treatment were not detailed in the abstract. Primary and secondary outcome measures were not specified.
Results
Not reported in abstract.
Interpretation
Without specific results, it is challenging to compare these findings to prior literature or to assess the clinical significance of any observed effects. The lack of detailed numeric findings limits the ability to draw firm conclusions about the efficacy of the drugs analyzed. Potential confounds include the absence of a clearly defined population and treatment protocols.
Key findings
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.